文献速递真菌感染

侵袭性木霉属感染:文献与FungiScope®登记病例的临床表现和结局

Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

该研究系统检索PubMed截至2021年12月的侵袭性木霉属感染病例,并加入FungiScope®登记病例进行联合分析,共纳入50例侵袭性感染。主要基础疾病为血液系统恶性肿瘤19例和持续不卧床腹膜透析10例,感染部位以肺部(42%)和腹膜(22%)最常见,总体死亡率为48%。

要点

  • 侵袭性木霉属感染共50例,血液系统恶性肿瘤19例、持续不卧床腹膜透析10例为主要基础疾病。
  • 感染部位以肺部(42%)和腹膜(22%)最常见。
  • 总体死亡率为48%,异基因造血干细胞移植受者为80%(4/5),实体器官移植受者为77%(7/9)。

核心结论

  • 尽管接受抗真菌治疗和手术,侵袭性木霉属感染仍是免疫抑制患者危及生命的并发症,尤其是造血干细胞移植和实体器官移植后。
  • 木霉属主要累及血液系统恶性肿瘤患者的肺部以及持续不卧床腹膜透析患者的腹膜。

研究设计与样本

  • 系统文献综述检索PubMed截至2021年12月的侵袭性木霉属感染病例,并查阅纳入研究的参考文献;将FungiScope®登记病例加入联合分析。
  • 共纳入50例侵袭性木霉属感染,其中11例来自FungiScope®登记。

主要发现

  • 主要基础疾病为血液系统恶性肿瘤19例和持续不卧床腹膜透析10例。
  • 感染部位以肺部(42%)和腹膜(22%)最常见。
  • 42例(84%)接受全身抗真菌治疗,以两性霉素B(n=27,其中脂质制剂13/27)和伏立康唑(n=15,30%)为主。
  • 13例(26%)接受手术干预。
  • 总体死亡率为48%(n=24);异基因造血干细胞移植受者死亡率为80%(4/5),实体器官移植受者为77%(7/9)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trichoderma spp. are filamentous fungi causing invasive fungal diseases in patients with haematological malignancies and in peritoneal dialysis patients. OBJECTIVES: To analyse clinical presentation, predisposing factors, treatment and outcome of Trichoderma infections. METHODS: A systematic literature review was conducted for published cases of invasive Trichoderma infection in PubMed until December 2021 and by reviewing the included studies' references. Cases from the FungiScope® registry were added to a combined analysis. RESULTS: We identified 50 invasive infections due to Trichoderma species, including 11 in the FungiScope® registry. The main underlying conditions were haematological malignancies in 19 and continuous ambulatory peritoneal dialysis (CAPD) in 10 cases. The most prevalent infection sites were lung (42%) and peritoneum (22%). Systemic antifungal therapy was administered in 42 cases (84%), mostly amphotericin B (n = 27, lipid-based formulation 13/27) and voriconazole in 15 cases (30%). Surgical interventions were performed in 13 cases (26%). Overall mortality was 48% (n = 24) and highest for allogeneic HSCT and solid organ transplantation (SOT) recipients [80% (4/5) and 77% (7/9), respectively]. In patients treated with amphotericin B, voriconazole and caspofungin, mortality was 55% (15/27), 46% (7/15) and 28% (2/7), respectively. Three out of four patients treated with a combination therapy of voriconazole and caspofungin survived. CONCLUSIONS: Despite treatment with antifungal therapies and surgery, invasive Trichoderma infections are life-threatening complications in immunocompromised patients, especially after HSCT and SOT. In addition, Trichoderma spp. mainly affect the lungs in patients with haematological malignancies and the peritoneum in CAPD patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sal E, Stemler J, Salmanton-García J, et al. Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry. J Antimicrob Chemother. 2022. PMID: 35929089. doi:10.1093/jac/dkac235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。